No Data
TONG REN TANG: INTERIM REPORT 2024
Concerns Surrounding Tong Ren Tang Technologies' (HKG:1666) Performance
The operation is fundamentally stable, and tong ren tang Technology (01666.HK) has entered a period of development dividends.
The concept of traditional Chinese medicine stocks in the Hong Kong stock market is a relatively "alternative" branch in the overall performance of the pharmaceutical sector in recent years. Looking at its underlying logic, on the one hand, it is due to the frequent blowing of favorable policies, which continuously brings bullish news to the traditional Chinese medicine industry and stimulates the performance of the capital markets. On the other hand, it is also due to the relatively lower valuations in this field compared to other subdivisions of the pharmaceutical industry. At the same time, the performance growth of traditional Chinese medicine companies, which are more consumer-oriented, has been quite strong, continuously boosting market confidence. Based on this, the traditional Chinese medicine sector has become one of the few sectors in the market that can withstand cyclical fluctuations. In recent years, the scale of the traditional Chinese medicine industry has continued to grow.
Tong Ren Tang Technologies Records 16% Higher Attributable Profit in H1
Tong Ren Tang Technology (01666) has released its interim results, with a net income attributable to the parent company of 0.429 billion yuan, an increase of 16.46% year-on-year.
Tong Ren Tang Technology (01666) released its interim performance for the six months ended June 30, 2024, and the group achieved revenue...
Express News | Tong Ren Tang Technologies H1 EPS RMB 0.33
The Five-year Shareholder Returns and Company Earnings Persist Lower as Tong Ren Tang Technologies (HKG:1666) Stock Falls a Further 6.9% in Past WeekNo Data
No Data
